Ventavis-Studie

Open-label, uncontrolled, prospective long-term observation of Ventavis inhalation therapy in the treatment of patients with primary pulmonary hypertension up to 4 years

 

BAY 63-2521 / IMP 12166

A multicenter, non-randomized, non-blinded, non-controlled study to investigate the impayt of multiple doses of BAY 63-2521 on safety, tolerability, pharmacokinetics, and

Pharmacodynamics in patients with pulmonary hypertension in a 12-week 3 times a day individual dose titration scheme

 

AMG 706-20050201-4067

A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination with Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer

 

AWB TOPS

Ein offenes, nicht-interventionelles Register, in dem Daten zur Sicherheit und Verträglichkeit von Thelin gesammelt werden (TOPS = Thelin Outcomes for Patients Surveillance)

 

SERAPHIN-Studie

AC-055-302 Study with Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome

AC-055-303 OL Study with an ERA in Pulmonary arterial Hypertension to Improve cliNical outcome (Open Label)

 

BAY 63-2521 / IMP 12916

A multi center, non-randomized, non-blinded, non-controlled study to investigate the impact of multiple doses of BAY 63-2521 on safety, tolerability, pharmacokinetics, and

pharmacodynamics in patients with interstitial lung disease and pulmonary hypertension

 

 TRANSFORMS-Extension

A 12-month double-blind, randomized, multicenter, active-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally

once daily versus interferion ß-1a (Avonex®) administered i.m. once weekly in patients with relapsind-remitting multiple sclerosis (Extensionsstudie)

 

 VOLT-Studie

A Post-Marketing Observational Surveillance Program for Ambrisentan

BAY 63-2521 / IMP 11348

A multicenter, randomized, double blind, placebo-controlled, two-arm study to assess the efficacy and safety of oral BAY 63-2521 in patients with inoperable chronic thromboembolic

pulmonary hypertension (CTEPH) or recurrent or persisting pulmonary hypertension after surgical treatment

 

 BAY 63-2521 / IMP 11349

Long-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg TID) in patients with chronic thromboembolic

pulmonary hypertension (CTEPH)

 

DETECT AC-052-510

A two-stage prospective observational cohort study in scleroderma patients to evaluate screening tests and the incidence of pulmonary arterial hypertension and pulmonary hypertension

 

BAY 63-2521 / IMP 12934

Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with

symptomatic Pulmonary Arterial Hypertension (PAH)

 

 BAY 63-2521 / IMP 12935

Long-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary

Arterial Hypertension (PAH)

 

Lungenfunktionsprüfungen

A 76-week prospective, open-label, multicenter study to evaluate the long-term effect Exelon® capsule and transdermal patch on worsening of the underlying motor symptoms of PD in

patients with mild to moderately severe dementia associated with Parkinson's disease

 

TERPAH-001   

Proof of Concept Study to Investigate the Efficacy, Hemodynamics and Tolerability vs. Placebo in Patients with Pulmonary Arterial Hypertension

 

Artemis-Studie

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early

Idiopathic Pulmonary Fibrosis (IPF)

IMPRES-Studie

A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the efficacy and safety or oral QTI571 as an add-on therapy in the treatment of severe pulmonary

arterial hypertension: Imatinib in Pulmonary arterial hypertension, a Randomized, Efficacy Study (IMPRES)

 

IMPRES-Extension-Studie

An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension: IMPRES

Extension

 

CTEPH-Studie

Double Blind Controlled Clinical Investigation into the Efficacy and Tolerability of subcutaneously administered Treprostinil Sodium in Patients with Severe (inoperable) Chronic

Thromboembolic Pulmonary Hypertension

 

FREEDOM-Studie

A 16 Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary

Arterial Hypertension

 

 FREEDOM-OL 

An Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension

 

BPS-MR-PAH 203

A 12-week, double-blind, international, multicenter, dose-response study of the safety and efficacy of Beraprost Sodium Modified Release (BPS-MR) in patients with pulmonary arterial

hypertension (PAH)

 

BPS-MR-PAH 204

An open-label extension of BPS-MR-PAH-203 in pulmonary arterial hypertension (PAH) patients

 

PROGRESS-CAP-Studie

Prospektive, längsschnittliche, multizentrische Fall-Kohortenstudie zur Progression r ambulant erworbenen Pneumonie

 

GRIPHON-Studie

A multicenter, doubl-blind, placebo-controlled Phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary arterial hypertension

 

BAY 63-2521 / 15096

Eine interaktive Studie zur Bewertung von Blutddruckveränderungen nach Einnahme von 1, 1.5, 2 oder 2.5 mg Riociguat (Dosistitration) im Vergleich zu Placebo bei Pateinten mit stabiler

Sildenafil Vorbehandlung, die eine symptomatische Pulmonale Arterielle Hypertonie aufweisen